AIDS TREATMENT NEWS Issue #355, November 17, 2000
John S. James
* The medical community is favorably impressed with Kaletra (lopinavir, formerly ABT-378, the newly-approved "second generation" protease inhibitor. A major Abbott trial presented 24-week data at ICAAC (40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000) and some 48-week data at the Fifth International Congress on Drug Therapy in HIV Infection (Glasgow, UK, October 22-26, 2000); complete 48- week data will be available at the Retroviruses conference (8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001). Stephen Becker, M.D., noted the impressive results with patients who were highly treatment experienced (but naive to the NNRTI class of antiretrovirals, in this trial). Also, very few patients discontinued the trial because of toxicity or because of virologic failure. Even patients with substantial resistance to other protease inhibitors were likely to do well.
Doctors do not agree on whether to reserve this drug for "salvage" therapy when other treatment options have failed, or to use it earlier in treatment, perhaps in initial therapy. At least at this time Dr. Becker chooses to wait and use it later.
Also, the development of Kaletra has been important as a "proof of concept" for the strategy of using a low dose of ritonavir (Norvir(R), another protease inhibitor from Abbott Laboratories) in order to keep another protease inhibitor in the body longer (by blocking a liver enzyme which destroys these drugs). Kaletra has the ritonavir included in the formulation, as it must be used with ritonavir or it would be eliminated from the body too quickly.
* Steven Deeks, M.D., discussed some of the most promising new HIV drugs in the pipeline. He named four: T-20, tipranovir (a new kind of protease inhibitor), DAPD, and tenofovir. All of these are active against many viruses which are highly resistant to other drugs.
He also noted that there is now much excitement about HIV integrase inhibitors, a major target for new drugs. But these are farther away, probably about five years from widespread use.
* Paul Volberding, M.D., discussed some of the major challenges of HIV research today, including acute infection (finding the cases is a challenge), finding people who are not currently in care so that they can be offered treatment, when to start antiretroviral therapy (the medical community has backed off from the "hit early" part of "hit hard, hit early"--but still treats hard, once one does start antiretrovirals). A survey of very experienced HIV physicians in San Francisco found that most started treatment at a CD4 count averaging around 350 (and some as late as a count of 200)--depending on other information about the patient, of course. The survey also found that combinations including the NNRTI drug class were the most popular to start with [as opposed to either protease inhibitors, or the triple nucleoside analog treatment with abacavir].
[Note that this community forum took place in November 2000, and treatment strategies later will be different. Sometimes our articles circulate on the Internet forever and are read as fresh information after they are no longer applicable.]
Other talks at the forum reviewed progress in preventive vaccines, and in microbicides to prevent HIV transmission.
001117
ATN35501
Copyright © 2000 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .